Abstract
SARS-CoV-2 remains a significant health threat due to its high infection and mutation rates. The emergence of new variants of concern poses challenges as they can lead to immune escape mutations, potentially reducing the efficacy of vaccines and antibody therapeutics. The receptor binding domain (RBD) of SARS-CoV-2 is particularly noteworthy as it is both the most rapidly evolving domain and the principal target of neutralizing antibodies. As an alternative to time-consuming and expensive neutralization assays, we have developed a bead-based multiplex surrogate virus neutralization test based on ACE2-RBD binding inhibition. We demonstrated how our high-throughput assay allows us to simultaneously assess anti-RBD neutralizing antibodies levels against multiple SARS-CoV-2 variants, providing data that is consistent with the gold-standard live virus neutralization assay. The utility of this assay was demonstrated by applying it to a large French population cohort to demonstrate that hybrid immunity (generated by a combination of vaccination and infection) is associated with protection against infection with the Omicron BA.1 and BA.2 lineages of SARS-COV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the European Research Council (MultiSeroSurv 852373 to M. W.), the French government's 'Integrative Biology of Emerging Infectious Diseases' (Investissement d'Avenir grant ANR-10-LABX-62-IBEID) and INCEPTION programs (Investissement d'Avenir grant ANR-16-CONV-0005). The COVID-Oise cohort is funded by Alliance Tous Unis Contre le Virus, Institut Pasteur, AP-HP, and Fondation de France.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Est II (Besancon) / Centre Hospitalier Régional d'Orléans gave ethical approval for this work This cohort clinical study aims to describe the kinetics of neutralizing antibodies after SARS-CoV-2 infection or vaccination (ClinicalTrials.gov identifier: NCT05315583). The cohort takes place in Orléans, France. This study was approved by the Est II (Besancon) ethical committee. At enrollment, written informed consent was collected, and participants completed a questionnaire that covered sociodemographic characteristics, clinical information and data related to anti-SARS-CoV-2 vaccination. Ethics committee of Comitéde Protection des Personnes Nord Ouest IV gave ethical approval for this work The study of the COVID-Oise cohort was registered with ClinicalTrials.gov (NCT04644159) and received ethical approval by the Comité de Protection des Personnes Nord Ouest IV. Ethics committee of Comité de Protection des Personnes Ile de France III gave ethical approval for this work Several COVID-Oise participants participated in the CORSER studies in spring 2020, registered with ClinicalTrials.gov (NCT04325646) and approved by the Comité de Protection des Personnes Ile de France III.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
